Tenax Therapeutics, Inc. TENX
1.66 USD -0.03 (-1.78%)
Nov 12, 2026, 1:40 PM EST
1.60 Day range 1.68
1.31 52-week range 19.40
- YTD
- -86.38%
- 1 year
- -76.25%
News
globenewswire.com TENX Investor Alert: Johnson Fistel Encourages Tenax Therapeutics, Inc. Investors to Contact the Firm Ahead of December 28, 2026 Lead Plaintiff Deadline SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a shareholder-rights law firm, announces that a securities class action lawsuit has been filed in the United States District Court…
prnewswire.com Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENX NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain…
newsfilecorp.com TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired…
globenewswire.com Deadline Alert: Tenax Therapeutics, Inc. Investors Have Until December 28, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors Class action covers investors who bought Tenax Therapeutics, Inc. securities between November 13, 2023 and August 7, 2026; complaint alleges the company failed to disclose material adverse facts…
newsfilecorp.com ROSEN, A TOP-RANKED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX New York, New York--(Newsfile Corp. - November 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between…
prnewswire.com TENX UPCOMING DEADLINE: Levi & Korsinsky Alerts Tenax Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm Alert: Claims Focus on Alleged Misrepresentations About the Phase 3 LEVEL Trial of TNX-103. Tenax shares lost nearly 90% of their value after an upsized study powered above 95% missed both its…
newsfilecorp.com TENX INVESTOR ALERT: Berger Montague Advises Tenax Therapeutics, Inc. (TENX) Investors of a December 28, 2026 Deadline Philadelphia, Pennsylvania--(Newsfile Corp. - November 11, 2026) - Berger Montague, a leading national plaintiffs' law firm, announces a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ:…
newsfilecorp.com SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
globenewswire.com SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
newsfilecorp.com Kaplan Fox Announces a Securities Class Action Filed Against Tenax Therapeutics, Inc. (TENX) - Lead Plaintiff Deadline is December 28, 2026 New York, New York--(Newsfile Corp. - November 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company")…
globenewswire.com Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain…
globenewswire.com ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13,…
prnewswire.com What's Next for Tenax Therapeutics, Inc. Shareholders After 89.77% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline Complaint alleges Tenax Therapeutics, Inc. misled investors between November 13, 2023 and August 7, 2026; investors may seek lead plaintiff role by December 28, 2026 LOS ANGELES, Nov. 10, 2026…
globenewswire.com TENX Shareholder Alert: Tenax Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt Guggenheim Securities cut its Tenax price target 90%, and two other firms downgraded TENX, after the Phase 3 LEVEL trial of TNX-103 failed. The lawsuit claims this study was wrongly promoted to…
businesswire.com Robbins LLP Urges TENX Investors Who Lost Money Investing in Tenax Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action SAN DIEGO--(BUSINESS WIRE)---- $TENX #TENX--Tenax Therapeutics, Inc. faces allegations it misled investors regarding the viability of its drug candidate levosimendan.
globenewswire.com TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tenax…
newsfilecorp.com ROSEN, LEADING INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX New York, New York--(Newsfile Corp. - November 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between…
zacks.com Tenax Therapeutics (TENX) Upgraded to Buy: Here's Why Tenax Therapeutics (TENX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
newsfilecorp.com TENX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired…
prnewswire.com Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TENX NEW YORK, Nov. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of…
globenewswire.com TENX DEADLINE: Levi & Korsinsky Reminds Tenax Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline The lawsuit asserts that Tenax Therapeutics used an FDA-cleared IND and an FDA-reviewed trial expansion to build confidence in TNX-103. The Phase 3 LEVEL study then failed, and TENX shares fell…
prnewswire.com INVESTOR DEADLINE: Tenax Therapeutics, Inc. (TENX) Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November…
prnewswire.com What Does Tenax Therapeutics, Inc.'s 89.77% Stock Drop Mean for Investors? The Law Offices of Howard G. Suit alleges Tenax Therapeutics, Inc. failed to disclose key facts to investors from November 13, 2023 through August 7, 2026; lead plaintiff deadline is December 28, 2026 BENSALEM TOWNSHIP, Pa.,…
businesswire.com Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TENX LOS ANGELES--(BUSINESS WIRE)---- $TENX--Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TENX.
gurufocus.com TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS LawPR NewswireLOS ANGELES, Nov. 9, 2026LOS ANGELES, Nov. 9, 2026 /
prnewswire.com TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES, Nov. 9, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
globenewswire.com SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
newsfilecorp.com ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX New York, New York--(Newsfile Corp. - November 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between…
newsfilecorp.com TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired…
prnewswire.com TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit NEW YORK, Nov. 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023…
globenewswire.com ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX NEW YORK, Nov. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13,…
newsfilecorp.com ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX New York, New York--(Newsfile Corp. - November 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between…
prnewswire.com TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES, Nov. 6, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of…
prnewswire.com Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TENX NEW YORK, Nov. 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of…
newsfilecorp.com Kaplan Fox Alerts Investors of Tenax Therapeutics, Inc. (TENX) with Significant Losses to a Securities Class Action Deadline on December 28, 2026 New York, New York--(Newsfile Corp. - November 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company")…
newsfilecorp.com ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX New York, New York--(Newsfile Corp. - November 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between…
prnewswire.com Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENX NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain…
prnewswire.com TENX Shareholder Alert: Tenax Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt Notice to Pension Funds, Asset Managers, and Fiduciaries: the lawsuit alleges Tenax overstated TNX-103's clinical prospects while raising $134 million, largely through private placements, before its…
newsfilecorp.com TENX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired…
benzinga.com Tenax Therapeutics Q3 EPS $(0.31) Beats $(0.40) Estimate Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.40) by 20.51 percent. This is a 22.5 percent increase over losses of…
globenewswire.com Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C.,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
benzinga.com 5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Month U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 350 points during the session. Renewed US-Iran strikes over the weekend sent crude sharply higher Monday, reviving…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million. CollPlant Biotechnologies (NASDAQ:CLGN)…
benzinga.com This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com Reported Earlier, Tenax Reports New Phase 3 Data Supporting TNX-103 In Pulmonary Hypertension Patients Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") today announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 (oral
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.2 million. Biodexa…
- benzinga.com Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5 Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
benzinga.com Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4 Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.